Ponatinib and pazopanib have been developed and approved as anti-cancer treatment, and their safety profiles have been evaluated in this context, with both drugs reported to cause severe side effects.62, 63 In this regard, chemical proteomic profiling of ponatinib identified several novel targets in addition to RIPK1 and RIPK3. Here, RIPK3 is linked to cancer.